OPDIVO (nivolumab) for Metastatic Squamous Non-Small Cell Lung Cancer

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for OPDIVO (nivolumab), indicated for metastatic squamous non-small cell lung cancer (NSCLC).

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 8: Use in Specific Populations
Slide 10: Clinical Pharmacology
Slide 14: Warnings and Precautions
Slide 18: Clinical Safety and Efficacy
Slide 27: Drug Storage and Supply
Slide 29: References

Next hm-slideshow in Slides